Onboard and engage patients into active partners in their healthcare journey.
Supporting and engaging new patients and caregivers with self-injection is a challenge faced by many pharmaceutical companies. This is why we created a solution to engage with patients, designed to properly onboard and train them when starting a new self-administered drug.
Discover our Patient Engagement Solution
The subcutaneous route offers numerous benefits, such as reduced healthcare costs and better convenience. But for it to be a success, onboarding patients at the beginning of their new self-injection therapy is key. Proper training, adequate instruction, and confidence-building are essential to overcome potential issues such as anxiety, lack of control or non-adherence. Implementing meaningful training, onboarding, and monitoring solutions for self-injection can empower patients, ensuring safe and effective treatment management in the comfort of their own homes.
Composed of an onboarding kit including an injector trainer, a mobile app, specific training and educational material around self-injection, our Patient Engagement Solution already demonstrated value.
Targeted therapies via subcutaneous route are becoming more common on the market and more prescribed by physicians. Moreover, auto-injector devices require patients to administer their own medication, sometimes on their own in their home. While they can be time and cost-effective, less than 50% of patients continue to adhere to their treatment after six months. A report from 2022 found that medication non-adherence costs are estimated to be between $100 to $290 billion in the United States and approximately 1.25 billion € in Europe annually (1).
(1) https://ilcuk.org.uk/doctors-orders/
Improvement in time to first injection administration (approx. 3.5 days sooner)
Improvement in time to ordering first refill
Improvement in achieving >80% PDC
Improvement in medication persistence at 6 months (approx. 2 additional doses)
Noble, an Aptar Pharma company, recently released the results of a pilot study conducted with a specialty pharmacy partner. The study demonstrated how providing patients with tailored training and onboarding resources at start of their self-administration journey helped them start sooner and stay longer on therapy. The positive study results are indicated by the stats above.
Our Patient Engagement Solution is a structured approach that healthcare providers use to involve patients more deeply in their care journeys. It goes beyond the traditional healthcare provider-patient relationship by fostering collaboration, communication, and empowerment.
Investing in Patient Engagement Solution aligns with the broader trend of personalized medicine and digital health, ensuring that pharma companies remain competitive and relevant in the evolving healthcare landscape.
Navigating from one device to another can be challenging for patients: gestures, techniques and side effects can be different. With the right onboarding and training program you can accelerate and derisk the transfer.
Engaged patients are more likely to adhere to treatment plans, attend follow-up appointments, and adopt healthy behaviors, leading to better health outcomes.
By actively involving patients, pharma companies can build stronger relationships, enhancing trust and loyalty.
Offering robust patient engagement solutions can differentiate a pharma company from its competitors, positioning it as a leader in patient-centric care.
Our program provides valuable data on patient experiences and outcomes, informing future strategies and improving overall healthcare delivery.
SHL Medical and Aptar Digital Health partnered to optimize the patient experience with self-injectable therapies. As part of this partnership, auto-injectors designed by SHL Medical, such as the Molly® Connected Cap – a smart retrofittable add-on for SHL Medical’s Molly® modular platform autoinjector – will benefit from Aptar Digital Health’s platform to enhance the patient experience by offering additional support during self-administration.
Read the announcement
Embarking on a new therapeutic journey can be overwhelming. Learn more about first-hand patient experience with self-injected therapies, their pain points and perspectives on how digital health solutions could enhance their experience.
Listen to patients’ feedback
Read about the integration of digital health and drug delivery to support subcutaneous injections in oncology, highlighting the benefits of this method, such as faster and less invasive administration. Aptar Digital Health & Gerresheimer emphasizes the importance of patient-centric solutions and digital health tools to overcome barriers to self-administration and improve patient outcomes.
Read the article
